Current Report Filing (8-k)
September 15 2020 - 12:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 11, 2020
Yew Bio-Pharm Group, Inc.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
000-54701
|
|
26-1579105
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
9460 Telstar Avenue, Suite 6
El Monte, California
|
|
91731
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (626)-401-9588
Not Applicable
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
YEWB
|
|
OTC Markets Group
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company. ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995
Information included in this Form 8-K may contain
forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”). This information may involve known and unknown risks, uncertainties and other
factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company”
or “Registrant”), to be materially different from future results, performance or achievements expressed or implied
by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future
plans, strategies and expectations, are generally identifiable by use of the words “may,” “will,” “should,”
“expect,” “anticipate,” “estimate,” “believe,” “intend” or “project”
or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based
on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any
forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or
implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes
no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other
events occur in the future.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Resignation of Director
On September 11, 2020, Mrs. Chang Liu and Mr.
Hengjiang Pang resigned as Directors of the Company, in order to pursue other interests and businesses. The Company thanks Mrs.
Liu and Mr. Pang for their service to the Company and wishes them the best in their future endeavors. There were no adverse reasons
for their resignations.
The openings will be filled by the Board after
its due diligence regarding the selection process.
Signature(s)
Pursuant to the Requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
|
Yew Bio-Pharm Group, Inc.
|
|
|
Date: September 15, 2020
|
By:
|
/s/ Zhiguo Wang
|
|
|
Zhiguo Wang
|
|
|
President & Chief Executive Officer
|
1
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From May 2024 to Jun 2024
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Jun 2023 to Jun 2024